ArticleAnnals of gastroenterology2021
Small bowel capsule endoscopy in refractory celiac disease: a luxury or a necessity?
Article in Annals of gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- European Society for the Study of Coeliac Disease 2025 Updated Guidelines on the Diagnosis and Management of Coeliac Disease in Adults. Part 1: Diagnostic Approach.United European gastroenterology journal · 2025Guideline
- First Brazilian expert consensus for video capsule endoscopy and balloon-assisted enteroscopy.Clinics (Sao Paulo, Brazil) · 2026Article
- Artificial intelligence-augmented small bowel capsule endoscopy for coeliac disease: a literature review on accuracy, workflow, and safety.Translational gastroenterology and hepatology · 2026Review
- Risk of malignancy and surveillance of premalignant gastrointestinal lesions in adult celiac disease.Frontiers in oncology · 2026Review
- Management Strategy for Non-Responsive and Refractory Celiac Disease in Adults: A Review Article.Journal of clinical medicine · 2025Review
- Past, Present, and Future of Noninvasive Tests to Assess Gluten Exposure, Celiac Disease Activity, and End-Organ Damage.Gastroenterology · 2024Review
- Guidelines for best practices in monitoring established coeliac disease in adult patients.Nature reviews. Gastroenterology & hepatology · 2024Review
- The Role of Capsule Endoscopy in the Diagnosis and Management of Small Bowel Tumors: A Narrative Review.Cancers · 2024Review
- Diffuse intestinal ulcerations: Diagnostic challenge in a patient with complicated celiac disease.DEN open · 2023Article
- Iron Deficiency in Celiac Disease: Prevalence, Health Impact, and Clinical Management.Nutrients · 2021Review
- Clinical Value of Tissue Transglutaminase Antibodies in Celiac Patients over a Long Term Follow-Up.Nutrients · 2021Article
- Editorial: Celebrating women researchers and a focus on non-invasive modalities and innovation.Therapeutic advances in gastrointestinal endoscopyArticle
- Navigating celiac disease with small bowel capsule endoscopy: current state and future horizons.Therapeutic advances in gastrointestinal endoscopyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSmall bowel capsule endoscopy (SBCE) has an established role in the management of refractory celiac disease (RCD) for the detection of complications. The aim of this study was to define the role of SBCE in the management of patients with RCD.
methodPatients with histologically confirmed RCD who underwent successive SBCEs were recruited retrospectively from 2 tertiary centers.
resultsSixty patients with RCD were included. The percentage extent of the affected small bowel (SB) mucosa improved on repeating a second SBCE in 26 patients (49.1%) (median 27.6% vs. 18.1%, P=0.007). Patients with RCD type II had more extensive disease than those with RCD type I on first (41.4% vs. 19.2%, P=0.004) and second (29.8% vs. 12.0%, P=0.016) SBCE. Patients with RCD type I tended to show a greater improvement in percentage of abnormal SB involved on repeat SBCE compared to those with RCD type II (P=0.049). Nine patients (15%) had RCD-related complications. Five patients developed ulcerative jejunoileitis, 3 patients developed enteropathy-associated T-cell lymphoma, and 1 patient developed cutaneous T-cell lymphoma.
conclusionsSBCE can be a useful tool for monitoring the effects of treatment, primarily following its initiation. Patients with RCD type II have more extensive SB disease, equating to a more aggressive disease pattern.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.